297 related articles for article (PubMed ID: 10544608)
21. Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).
Wijermans PW; Rüter B; Baer MR; Slack JL; Saba HI; Lübbert M
Leuk Res; 2008 Apr; 32(4):587-91. PubMed ID: 17881052
[TBL] [Abstract][Full Text] [Related]
22. Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution.
Breccia M; Latagliata R; Mengarelli A; Biondo F; Mandelli F; Alimena G
Haematologica; 2004 Jul; 89(7):866-8. PubMed ID: 15257942
[TBL] [Abstract][Full Text] [Related]
23. Blastic Transformation in Mexican Population With Chronic Myelomonocytic Leukemia.
Rivera Duarte A; Armengol Alonso A; Sandoval Cartagena E; Tuna Aguilar E
Clin Lymphoma Myeloma Leuk; 2017 Aug; 17(8):532-538. PubMed ID: 28842140
[TBL] [Abstract][Full Text] [Related]
24. Chronic myelomonocytic leukemia with antecedent refractory anemia with excess blasts: further evidence for the arbitrary nature of current classification systems.
Breccia M; Cannella L; Frustaci A; Stefanizzi C; D'Elia GM; Alimena G
Leuk Lymphoma; 2008 Jul; 49(7):1292-6. PubMed ID: 18604717
[TBL] [Abstract][Full Text] [Related]
25. High spontaneous colony growth in chronic myelomonocytic leukemia correlates with increased disease activity and is a novel prognostic factor for predicting short survival.
Sagaster V; Ohler L; Berer A; Kabrna E; Ofner P; Lechner K; Geissler K
Ann Hematol; 2004 Jan; 83(1):9-13. PubMed ID: 13680175
[TBL] [Abstract][Full Text] [Related]
26. Chronic myelomonocytic leukemia treated with 5-azacytidine - results from the Hellenic 5-Azacytidine Registry: proposal of a new risk stratification system.
Diamantopoulos PT; Kotsianidis I; Symeonidis A; Pappa V; Galanopoulos A; Gogos D; Karakatsanis S; Papadaki H; Palla A; Hatzimichael E; Dimou M; Papageorgiou S; Delimpasis S; Papaioannou M; Papoutselis M; Kourakli A; Tsokanas D; Anagnostopoulos A; Kontos CK; Panayiotidis P; Viniou NA;
Leuk Lymphoma; 2019 Jul; 60(7):1721-1730. PubMed ID: 30424699
[TBL] [Abstract][Full Text] [Related]
27. Prognostic factors in the myelodysplastic syndromes: importance of initial data on peripheral blood counts, bone marrow cytology, trephine biopsy and chromosomal analysis.
Tricot G; Vlietinck R; Boogaerts MA; Hendrickx B; De Wolf-Peeters C; Van den Berghe H; Verwilghen RL
Br J Haematol; 1985 May; 60(1):19-32. PubMed ID: 3859319
[TBL] [Abstract][Full Text] [Related]
28. 3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis.
Hu Z; Hu S; Ji C; Tang Z; Thakral B; Loghavi S; Medeiros LJ; Wang W
Leuk Res; 2018 Feb; 65():25-28. PubMed ID: 29288910
[TBL] [Abstract][Full Text] [Related]
29. Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system.
Aul C; Gattermann N; Heyll A; Germing U; Derigs G; Schneider W
Leukemia; 1992 Jan; 6(1):52-9. PubMed ID: 1736014
[TBL] [Abstract][Full Text] [Related]
30. [Significance and application value of multiparameter flow cytometry for differentiation of immunophenotype in chronic myelomonocytic leukemia, myelodysplastic syndrome and acute monocytic leukemia].
Wang YX; Zhang JH; Hu YP; Cao FF; Zhang N; Chen F; Liu X; Zhang MY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2012 Aug; 20(4):857-62. PubMed ID: 22931642
[TBL] [Abstract][Full Text] [Related]
31. A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia. Groupe Français des Myélodysplasies and European CMML Group.
Wattel E; Guerci A; Hecquet B; Economopoulos T; Copplestone A; Mahé B; Couteaux ME; Resegotti L; Voglova V; Foussard C; Pegourié B; Michaux JL; Deconinck E; Stoppa AM; Mufti G; Oscier D; Fenaux P
Blood; 1996 Oct; 88(7):2480-7. PubMed ID: 8839839
[TBL] [Abstract][Full Text] [Related]
32. Immunophenotype in chronic myelomonocytic leukemia: is it closer to myelodysplastic syndromes or to myeloproliferative disorders?
Subirá D; Font P; Villalón L; Serrano C; Askari E; Góngora E; Castañón S; Gonzalo R; Mata R; Román A; Llamas P
Transl Res; 2008 May; 151(5):240-5. PubMed ID: 18433705
[TBL] [Abstract][Full Text] [Related]
33. Clinical and hematological aspects of chronic myelomonocytic leukemia. Study on 20 cases from a single center from Romania.
Gologan R; Berceanu A; Colita A; Codreanu V; Dobrea C; Geoada L; Iacob V; Niculescu-Mizil E; Ostroveanu D; Puşcariu T; Ursuleac I
Rom J Intern Med; 2002; 40(1-4):95-102. PubMed ID: 15526545
[TBL] [Abstract][Full Text] [Related]
34. Myelodysplastic syndromes without peripheral monocytosis but with evidence of marrow monocytosis share clinical and molecular characteristics with CMML.
Schuler E; Frank F; Hildebrandt B; Betz B; Strupp C; Rudelius M; Aul C; Schroeder T; Gattermann N; Haas R; Germing U
Leuk Res; 2018 Feb; 65():1-4. PubMed ID: 29216536
[TBL] [Abstract][Full Text] [Related]
35. Chronic Myelomonocytic Leukemia With Fibrosis Is a Distinct Disease Subset With Myeloproliferative Features and Frequent JAK2 p.V617F Mutations.
Gur HD; Loghavi S; Garcia-Manero G; Routbort M; Kanagal-Shamanna R; Quesada A; Khogeer H; Pierce S; Medeiros LJ; Kantarjian H; Khoury JD
Am J Surg Pathol; 2018 Jun; 42(6):799-806. PubMed ID: 29596070
[TBL] [Abstract][Full Text] [Related]
36. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia.
Beran M; Estey E; O'Brien SM; Giles FJ; Koller CA; Kornblau S; Keating M; Kantarjian HM
Leuk Lymphoma; 1998 Nov; 31(5-6):521-31. PubMed ID: 9922042
[TBL] [Abstract][Full Text] [Related]
37. Prognostic significance of monocytosis in patients with myeloproliferative disorders.
Beran M; Shen Y; Onida F; Wen S; Kantarjian H; Estey E
Leuk Lymphoma; 2006 Mar; 47(3):417-23. PubMed ID: 16396764
[TBL] [Abstract][Full Text] [Related]
38. Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
Patnaik MM; Vallapureddy R; Yalniz FF; Hanson CA; Ketterling RP; Lasho TL; Finke C; Al-Kali A; Gangat N; Tefferi A
Am J Hematol; 2018 Jan; 93(1):65-73. PubMed ID: 29023992
[TBL] [Abstract][Full Text] [Related]
39. Association of bone marrow fibrosis with inferior survival outcomes in chronic myelomonocytic leukemia.
Khan M; Muzzafar T; Kantarjian H; Badar I; Short N; Wang X; Chamoun K; Jain P; DiNardo C; Pemmaraju N; Bose P; Borthakur G; Cortes J; Verstovsek S; Garcia-Manero G; Estrov Z
Ann Hematol; 2018 Jul; 97(7):1183-1191. PubMed ID: 29557496
[TBL] [Abstract][Full Text] [Related]
40. Development and validation of a prognostic scoring system for patients with chronic myelomonocytic leukemia.
Such E; Germing U; Malcovati L; Cervera J; Kuendgen A; Della Porta MG; Nomdedeu B; Arenillas L; Luño E; Xicoy B; Amigo ML; Valcarcel D; Nachtkamp K; Ambaglio I; Hildebrandt B; Lorenzo I; Cazzola M; Sanz G
Blood; 2013 Apr; 121(15):3005-15. PubMed ID: 23372164
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
